Trial Profile
A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45 mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 09 Sep 2022 Timeframe for primary endpoint reduced from 48 weeks to 24 weeks.
- 15 Jan 2021 Status changed from recruiting to active, no longer recruiting.